Approved comparison material connected to this topic.
3 total recordsSource comparisons are presented without a generated winner.
Semaglutide 2.4mg GLP-1 only 14.9% (STEP-1) 68% fat, 32% lean 35% FDA-approved (Wegovy) Tirzepatide 15mg GLP-1/GIP dual 20.9% (SURMOUNT-1) 78% fat, 22% lean 42% FDA-approved (Zepbound) Survodutide 6.0mg GLP-1/…
The SYNCHRONIZE-COMPARE trial, a 48-week randomised controlled study published in The Lancet in late 2025, directly compared survodutide 6.0mg weekly to semaglutide 2.4mg weekly in 1,248 participants with BMI …
Before selecting a peptide protocol, understanding mechanism-specific outcomes matters more than generic 'fat loss' claims. This table compares the three most-researched peptide classes for visceral fat reduct…